# ASX Announcement

**4 August 2026**

Neurotech International

## Receipt of Binding Commitments for ~$4.5m Placement

*Neurotech expects to be fully funded through to topline data readout for the NTI164 Phase III ASD "Beyond Harmony" clinical trial upon completion of Placement*

**Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company")**, a clinical-stage biopharmaceutical company focused on paediatric neurological disorders, is pleased to announce that, following strong demand, it has received binding commitments from investors totalling approximately $4.5 million (before costs) through the placement of approximately 321.4[1] million new fully paid ordinary shares ("Placement Shares") at an issue price of $0.014 per share ("Placement").

The Placement was supported by existing and new institutional and sophisticated investors and was managed by Taylor Collison Limited and Canary Capital Pty Ltd as Joint Lead Managers.

Funds raised will predominantly be used to fund the Company's Phase III double-blind, placebo-controlled clinical trial of NTI164 in children with Autism Spectrum Disorder (ASD), as well as regulatory activities, general working capital and costs associated with the Placement. Further details regarding the Placement are set out in Annexure A.

Subject to completion of the Placement, based on Neurotech's current clinical development plan and budget, and together with its existing cash, the Company expects that the net proceeds of the Placement will fund Neurotech through to topline data readout from the Phase III clinical trial which is anticipated to represent a significant milestone in the Company's development pathway for NTI164.

Neurotech's Managing Director and CEO, Dr Anthony Filippis, said:

*"We are pleased to have secured support from new and existing shareholders, enabling Neurotech to progress NTI164 through its Phase 3 clinical program. This capital raising provides the Company with the cash runway to deliver the next major value inflection point for NTI164."*

Neurotech remains focused on executing its global development strategy for NTI164, with the objective of addressing significant unmet needs in ASD and progressing towards potential regulatory approval and commercialisation.

### Authority

This announcement was authorised for release by the Board of Neurotech International Limited.

**For further information contact us via info@neurotechinternational.com**

### About NTI164

NTI164 is a proprietary, multi-constituent, GMP-grade standardised formulation containing CBDA-rich extracts and select minor cannabinoids. Preclinical and earlier clinical findings have demonstrated its potential to modulate neuroinflammatory signalling, immune dysregulation and upstream biological mechanisms implicated in neurodevelopmental disorders.

(1) This number includes 28,100,295 shares agreed to be issued subject to shareholder approval.

## About Neurotech

**Neurotech International Limited (ASX:NTI)** is a clinical-stage biopharmaceutical development company focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, doubleblind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase III Clinical Study in ASD.

For more information about Neurotech please visit http://www.neurotechinternational.com.

## Forward Looking Statements

This announcement includes forward-looking statements, including forward-looking statements relating to the future operation of the Company. These forward-looking statements are based on the Company's expectations and beliefs concerning future events. Forward-looking statements are necessarily subject to risks, uncertainties and other factors, many of which are outside the control of the Company, which could cause actual results to differ materially from such statements. The Company makes no undertaking to subsequently update or revise the forward-looking statements made in this announcement to reflect the circumstances or events after the date of this announcement. There is no guarantee that the Phase 3 study will be successful or that NTI164 will receive regulatory approval. You are strongly cautioned not to place undue reliance on forward-looking statements.

**Annexure A - Placement Details**

| Placement | Details |
|---|---|
| Issue price | $0.014 per share |
| Placement Structure | Approximately 321.4 million to be issued in two tranches (with the Tranche 2 Placement Shares being subject to shareholder approval)<br><br>Tranche 1:<br>• Approximately $4.1 million<br>• 161,054,109 shares to be issued to non-related parties under the Company's existing capacity under Listing Rule 7.1<br>• 132,274,168 shares to be issued to non-related parties under the Company's existing capacity under Listing Rule 7.1A<br>Tranche 2:<br>• Approximately $0.4 million<br>• 28,100,294 shares agreed to be issued to non-related parties subject to shareholder approval at a future General Meeting of shareholders ("Tranche 2 Placement Shares") |
| Total funds raised | Approximately $4.5 million (before costs) |
| Expected Tranche 1 Settlement date* | Thursday, 13 August 2026 |
| Expected Issue date of Tranche 1 Placement Shares* | Friday, 14 August 2026 |
| General Meeting date to approve Tranche 2 Shares* | In or around September 2026 |
| Tranche 2 Settlement date* | In or around September 2026 |
| Issue date of Tranche 2 Placement Shares* | In or around September 2026 |
| Joint Lead Managers | • Taylor Collison Limited ("TC") and Canary Capital Pty Ltd acted as the Joint Lead Managers of the Company's Placement and will receive a 1% management fee and 4% selling fee<br>• Subject to shareholder approval, Neurotech has agreed to issue the following options to TC (or its nominee(s)) as part consideration for TC's services acting as Joint Lead Managers to the Company's Placement:<br>  o 11.25 million unlisted options ($0.02, expiring 2 years from their date of issue)<br>  o 11.25 million unlisted options ($0.035, expiring 3 years from their date of issue) |

*The above settlement and issue dates are indicative only and may vary, subject to the requirements of the ASX Listing Rules.